Investors - Imexpharm

Financial information

IMP - Disclosure of reviewed 6 month 2025 Financial statements and explanation for PAT growth

IMP - 2Q and 6M 2025 Business Results

IMP - Press release: Second Quarter and First Half 2025 Results

IMP - Disclosure of Q2.2025 Financial Statements and Explanation for PAT growth

IMP - 5M2025 Business Updates

IMP - 1Q and 4M 2025 Business Results

IMP - Press release: Imexpharm Corporation announces first quarter 2025 results

IMP - Financial Statement Q1. 2025

IMP - Audited Financial Statements for the year end 31 Dec 2024

IMP - 2Q and 6M 2025 Business Results

IMP - Press release: Second Quarter and First Half 2025 Results

IMP - 5M2025 Business Updates

IMP - 1Q and 4M 2025 Business Results

IMP - Press release: Imexpharm Corporation announces first quarter 2025 results

IMP - 2M2025 Business Updates

Imexpharm - VAD investor presentation

IMP - 4Q2024 and FY2024 business results

Imexpharm Facts & Figures 2024

IMP - Disclosure of reviewed 6 month 2025 Financial statements and explanation for PAT growth

IMP - Disclosure of Q2.2025 Financial Statements and Explanation for PAT growth

IMP - Financial Statement Q1. 2025

IMP - Audited Financial Statements for the year end 31 Dec 2024

IMP - Financial Statements Q4. 2024

IMP - Financial Statements Q3. 2024

IMP - Explanation of 1H2024 financial statements

IMP - Reviewed Interim Financial Statements 1H2024

IMP - Explanation of 2Q2024 financial statements

Annual Report & Sustainability Report

Annual Report 2024 (Digital version)

Annual Report 2024 (Digital version)

Sustainability Report 2024

Sustainability Report 2024

Annual Report 2024 (PDF version)

Annual Report 2024 (PDF version)

Sustainability Report 2023

Sustainability Report 2023

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Sustainability Report 2022

Sustainability Report 2022

Annual Report 2022

Annual Report 2022

Sustainability Report 2021

Sustainability Report 2021

Annual Report 2024 (Digital version)

Annual Report 2024 (Digital version)

Annual Report 2024 (PDF version)

Annual Report 2024 (PDF version)

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Annual Report 2022

Annual Report 2022

Annual Report 2021

Annual Report 2021

Annual Report 2020

Annual Report 2020

Annual Report 2019

Annual Report 2019

Annual Report 2018

Annual Report 2018

Sustainability Report 2024

Sustainability Report 2024

Sustainability Report 2023

Sustainability Report 2023

Sustainability Report 2022

Sustainability Report 2022

Sustainability Report 2021

Sustainability Report 2021

Sustainability Report 2020

Sustainability Report 2020

Sustainability Report 2019

Sustainability Report 2019

Sustainability Report 2018

Sustainability Report 2018

AGM

IMP - Official letter amending the Resolution and Minutes of the 2025 AGM

05/15/2025

IMP - Meeting minutes of the 2025 AGM

04/26/2025

IMP - Resolution of the 2025 AGM

04/26/2025

IMP - Documents for the 2025 Annual General Meeting of Shareholders

04/03/2025

IMP - Announcement attend the AGM 2025

03/28/2025

IMP - Resolution of the GMS No. 04 approving the implementation of the Cat Khanh Pharmaceutical Factory Complex Project

10/30/2024

IMP - Resolution of the GMS No. 03 approving certain issues by collecting written opinions

10/30/2024

IMP - Minutes of voting checking results of shareholders' written opinions (2nd time in 2024)

10/30/2024

IMP - Documents for the 2025 Annual General Meeting of Shareholders

04/03/2025

IMP - Announcement attend the AGM 2025

03/28/2025

IMP - Documents to collect GMS's opinions in writing (2nd time in 2024)

10/17/2024

IMP - Documents to collect GMS's opinions in writing

07/25/2024

IMP - Documents of the 2024 AGM

04/05/2024

IMP - Announcement attend the AGM 2024

03/26/2024

IMP - Document for obtaining written opinions of the GMS 2023

11/27/2023

IMP - Invitation and Documents of the 2023 AGM

03/29/2023

IMP - Official letter amending the Resolution and Minutes of the 2025 AGM

05/15/2025

IMP - Meeting minutes of the 2025 AGM

04/26/2025

IMP - Resolution of the 2025 AGM

04/26/2025

IMP - Resolution of the GMS No. 04 approving the implementation of the Cat Khanh Pharmaceutical Factory Complex Project

10/30/2024

IMP - Resolution of the GMS No. 03 approving certain issues by collecting written opinions

10/30/2024

IMP - Minutes of voting checking results of shareholders' written opinions (2nd time in 2024)

10/30/2024

IMP - Resolution of the GMS to collect shareholders' written opinions

08/08/2024

IMP - Minutes of voting checking results of shareholders' written opinions

08/08/2024

Corporate Governance

IMP - Report on Corporate Governance for 1H2025

07/25/2025

IMP - Imexpharm's Charter - April 2025 (amended on May 15, 2025)

05/15/2025

IMP - Internal regulations on Corporate Governance - April 2025

04/26/2025

IMP - Imexpharm's Charter - April 2025

04/26/2025

IMP - Nomination and Compensation Committee Regulation

02/24/2025

IMP - Regulation on operation of Audit Committee

02/24/2025

IMP - Report on Corporate Governance for 2024

01/23/2025

IMP - Imexpharm's Charter - October 2024

10/01/2024

IMP - Imexpharm's Charter - April 2025 (amended on May 15, 2025)

05/15/2025

IMP - Internal regulations on Corporate Governance - April 2025

04/26/2025

IMP - Imexpharm's Charter - April 2025

04/26/2025

IMP - Nomination and Compensation Committee Regulation

02/24/2025

IMP - Regulation on operation of Audit Committee

02/24/2025

IMP - Imexpharm's Charter - October 2024

10/01/2024

IMP - Imexpharm's Charter - July 2024

07/29/2024

IMP - Internal regulations on Corporate Governance - April 2024

04/27/2024

IMP - Report on Corporate Governance for 1H2025

07/25/2025

IMP - Report on Corporate Governance for 2024

01/23/2025

IMP - Report on Corporate Governance for 1H2024

07/30/2024

IMP: Report on Corporate Governance in 2023

01/30/2024

IMP: Report on Corporate Governance for the First 6 months of 2023

07/28/2023

IMP – Report on Corporate Governance in 2022

01/30/2023

IMP - Report on Corporate Governance for 1H2022

07/25/2022

IMP – Report on Corporate Governance in 2021

01/24/2022

Imexpharm – Prospectus for Public Offering of Shares 2010

11/16/2010

Information Disclosure

IMP - Resolution No. 09 of the BOD on the exercise of rights to subscribe for shares under the Share issuance Plan to existing shareholders of Agimexpharm

08/15/2025

IMP - Disclosure of reviewed 6 month 2025 Financial statements and explanation for PAT growth

08/14/2025

IMP - Report on Corporate Governance for 1H2025

07/25/2025

IMP - Disclosure of cancellation of the Power of Attorney to disclose information

07/21/2025

IMP - Change in personnel: Dismissal of Mr. Nguyen An Duy

07/21/2025

IMP - Resolution No. 08 of the BOD on the dismissal of the Deputy General Director cum CFO

07/21/2025

IMP - Disclosure of Q2.2025 Financial Statements and Explanation for PAT growth

07/18/2025

IMP - Disclosing on signing the audit contract for the fiscal year 2025

07/04/2025

Analyst Report

Analyst Report

SSI - Valuation update report

FPTS - Valuation update report

PHS - Flash Note: Leading position, Sustainable growth

PHS - Company meeting note

SSI - Positive Outlook for 2H and Beyond

VDSC - Business update 1Q2024

Vietcap - Visit note

FPTS - Valuation update report

ACBS - Flash Note IMP

News - Events

1H2025 - Imexpharm Facts & Figures

07/21/2025

1H2025 - Imexpharm Facts & Figures

CSA 2025 honors Imexpharm for sustainable journey toward community and environment

07/16/2025

CSA 2025 honors Imexpharm for sustainable journey toward community and environment

Imexpharm 1H2025 Earnings Call Invitation

Imexpharm 1H2025 Earnings Call Invitation

07/14/2025

1Q2025 - Imexpharm Facts & Figures

1Q2025 - Imexpharm Facts & Figures

05/07/2025

Imexpharm 1Q2025 Earnings Call Invitation

Imexpharm 1Q2025 Earnings Call Invitation

05/05/2025

Imexpharm targets VND2,981 billion in total revenue at 2025, up 18,6%

Imexpharm targets VND2,981 billion in total revenue at 2025, up 18,6%

04/25/2025

Top 50 best listed companies

Top 50 best listed companies

In 2024, Imexpharm was voted Top 50 best listed companies of the year by Forbes Vietnam Magazine. Being named on the list for the third time, Imexpharm shows its solid preparation of internal strength, ready for the next steps on its 47-year development journey.